NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
78.92 -0.08 (-0.10%) GOLD FUTURES
2,315.90 +4.90 (+0.21%) DOW
38,162.93 +259.64 (+0.69%) Bitcoin GBP
47,342.43 +1,482.22 (+3.23%)
Blueprint Medicines Corporation (BPMC)
| Previous close | 94.86 |
| Open | 104.20 |
| Bid | 109.01 x 200 |
| Ask | 109.77 x 100 |
| Day's range | 100.90 - 110.13 |
| 52-week range | 43.89 - 110.13 |
| Volume | |
| Avg. volume | 813,908 |
| Market cap | 6.866B |
| Beta (5Y monthly) | 0.65 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the first quarter ended March 31, 2024, and provided updated financial guidance.
- PR Newswire
Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 2, 2024, to report its first quarter 2024 financial results and provide a corporate update.
- PR Newswire
Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced it will launch a webcast series to provide scientific perspectives and showcase the company's research and development strategy. The first event in this series will feature Dr. Mariana Castells, a renowned leader in mast cell research and clinical expert in allergic/inflammatory diseases, as a guest speaker.
